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Background: Human menstrual blood-derived stem cells (MenSCs) are a novel source of MSCs that provide the
advantage of being easy to collect and isolate. Exosomes contain some mRNAs and adhesion molecules that can
potentially impact cellular and animal physiology. This study aimed to investigate the therapeutic potential of
MenSC-derived exosomes (MenSC-Ex) on AML12 cells (in vitro) and D-GalN/LPS-induced FHF mice (in vivo).
Methods: Transmission electron microscopy and Western blot were used to identify MenSC-Ex. Antibody array was
used to examine cytokine levels on MenSC-Ex. MenSC-Ex were treated in D-GalN/LPS-induced AML12 in vitro. Cell
proliferation and apoptosis were measured. MenSC-Ex were injected into the tail veins of mice 24 h before treatment
with D-GalN/LPS. Blood and liver tissues served as physiological and biochemical indexes. The number of liver
mononuclear cells (MNCs) and the amount of the active apoptotic protein caspase-3 were determined to
elaborate the mechanism of hepatoprotective activity.
Results: Human menstrual blood-derived stem cell-derived exosomes (MenSC-Ex) are bi-lipid membrane vesicles
that have a round, ball-like shape with a diameter of approximately 30–100 nm. Cytokine arrays have shown that
MenSC-Ex expressed cytokines, including ICAM-1, angiopoietin-2, Axl, angiogenin, IGFBP-6, osteoprotegerin, IL-6,
and IL-8. MenSC-Ex markedly improved liver function, enhanced survival rates, and inhibited liver cell apoptosis at
6 h after transplantation. MenSC-Ex migrated to sites of injury and to AML12 cells (a mouse hepatocyte cell line),
respectively. Moreover, MenSC-Ex reduced the number of liver mononuclear cells (MNCs) and the amount of the
active apoptotic protein caspase-3 in injured livers.
Conclusions: In conclusion, our results provide preliminary evidence for the anti-apoptotic capacity of MenSC-Ex
in FHF and suggest that MenSC-Ex may be an alternative therapeutic approach to treat FHF.
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Clinical fulminant hepatic failure (FHF) causes relatively
high mortality and affected patients present with very se-
vere clinical symptoms, such as coagulopathy, jaundice,
and multiorgan failure. However, the only clinical treat-
ment for FHF is liver transplantation, which is limited
by a shortage of donor livers [1].
D-galactosamine (D-GalN) and lipopolysaccharide (LPS)
co-induce (D-GalN/LPS) FHF in mice, producing a* Correspondence: cxiang@zju.edu.cn
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therefore commonly used as a test model [2]. LPS is the
main component of Gram-negative bacterial cell walls,
which induce very strong immunogenicity and can en-
hance immune response. When D-GalN/LPS are applied in
mice, LPS activates immune cells in the liver, including
monocytes, macrophages, and hepatic Kupffer cells [3].
Human menstrual blood-derived stem cells (MenSCs)
are human menstrual blood progenitor cells (MBPCs)
that are isolated from menstrual fluids [4–6]. MenSCs
are similar to mesenchymal stem cells (MSCs), which have
proliferative capabilities and broad multipotency, includ-
ing the ability to differentiate into cell types belonging tole is distributed under the terms of the Creative Commons Attribution 4.0
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liferation rates than bone marrow-derived MSCs and can
be easily obtained without invasive procedures [9–11]. In
particular, our and other groups have reported that
MenSCs induce low-level immunogenicity in clinical stud-
ies and can be expanded through at least 20 passages with-
out genetic abnormalities [9, 12, 13]. The therapeutic
potential of MenSCs has been demonstrated in several
disease models, such as Duchenne muscular dystrophy,
stroke, type 1 diabetes, premature ovarian failure, and
myocardial infarction. These studies have suggested that
MenSC-based therapies may be developed into future
clinical applications [12, 14–19].
Exosomes are bi-lipid membrane vesicles that have a
diameter of 50–100 nm and are secreted by various cell
types. Exosomes carry a complex cargo load of proteins
and RNAs that can potentially impact cellular and ani-
mal physiology. Studies have shown that exosomes are
involved in complex physiological processes, such as
intercellular communication, antigen presentation, and
immune responses [20]. High-performance liquid chro-
matography (HPLC) and dynamic light scatter (DLS)
analyses revealed that MSCs secrete cardioprotective mi-
croparticles with diameters ranging from 50 to 65 nm
[21, 22]. Furthermore, Lai et al reported that the thera-
peutic efficacy of exosomes derived from human embry-
onic stem cell-derived MSCs were similar to exosomes
derived from other fetal tissue sources (e.g., the limbs
and kidneys), demonstrating that MSC-derived exosomes
display general therapeutic properties [23].
Silymarin, a milk thistle of Silybum marianum, is the
well-researched drug in the treatment of liver disease
[24]. It has been found that silymarin has hepatoprotective,
anti-oxidant, anti-inflammatory activities [25]. Silymarin is
in our study as a reference drug to compare the beneficial
effects achieved by human menstrual blood-derived stem
cell-derived exosomes (MenSC-Ex).
Because of these advantages, we sought to investigate
the therapeutic potential of MenSC-Ex in D-GalN/LPS-
induced FHF. There were two purposes to this study.
First, we sought to investigate the therapeutic effects of
MenSC-Ex on AML12 cells (in vitro) and D-GalN/LPS-
induced FHF mice (in vivo). Second, we sought to iden-
tify the mechanism underlying the MenSC-Ex-mediated
inhibition of liver apoptosis.
Methods
Animals
Six- to eight-week-old male C57BL/6 mice were pur-
chased from Sippr-BK Laboratory Animal Corporation
(Shanghai, China). The mice were fed food and water ad
libitum and housed under standard conditions with a
12 h light and 12 h dark cycle. All animal experiments
were approved by the Laboratory Animal Center of TheTab of Animal Experimental Ethical Inspection of the
First Affiliated Hospital, College of Medicine, Zhejiang
University.
Cell culture
MenSCs were isolated and maintained as previously de-
scribed [4, 12]. The MenSCs were collected and cultured
in Chang Medium (S-Evans Biosciences, Hangzhou, China).
The MenSCs used in the experiments were at the fourth to
eighth passage.
The mouse AML12 hepatocyte cell line was gener-
ously provided by the Stem Cell Bank of the Chinese
Academy of Sciences. AML12 cells were cultured in
DMEM/F12 (Gibco, Waltham, MA, USA) supplemented
with 10% fetal bovine serum (FBS; Gibco), 100 IU/mL of
penicillin (Sigma-Aldrich, St. Louis, MO, USA), 100 μg/
mL of streptomycin (Sigma-Aldrich), insulin, transferrin,
selenium (ITS) Liquid Media Supplement (Sigma-Aldrich,
USA) and 40 ng/ml dexamethasone (Sigma-Aldrich, USA).
Identification of MenSCs using flow cytometry
The expression of isolated MenSCs surface markers was
evaluated using fluorescence-activated cell sorting (FACS).
Briefly, 5 × 105 cells were collected and washed twice with
stain buffer (BD Biosciences, San Jose, CA, USA). MenSCs
were incubated in the dark for 20 min with the following
primary antibodies: PE-conjugated CD29, CD34, CD45,
CD73, CD90, CD105, CD117, and HLA-DR (Becton
Dickinson, Franklin Lakes, NJ, USA). The stained cells
were washed twice with stain buffer, resuspended in
500 μl of stain buffer and then analyzed using a FC500
flow cytometer (Beckman Coulter, Brea, CA, USA). IgG1
(Becton Dickinson, Franklin Lakes, NJ, USA) was used as
an isotype control for the anti-CD29, anti-CD34, anti-
CD45, anti-CD73, anti-CD90, anti-CD105, and anti-
CD117 antibodies. IgG2a (Becton Dickinson) was used as
the isotype control for the anti-HLA-DR antibody. The re-
sults were analyzed using FlowJo software (Tree Star, Inc.,
Ashland, OR, USA).
CFU-F assay
The colony-forming unit-fibroblast (CFU-F) assay was
determined as described previously [26]. MenSCs plated
at 50, 150, or 250 cells per square centimeter. After
15 days of culture, cells were stained with 20% crystal
violet solution for 15 min at room temperature. After
phosphate-buffered saline (PBS) wash, the numbers of
individual colonies were counted. Three independent ex-
periments were performed.
Isolation and identification of MenSC-Ex
When MenSCs reached 70–80% confluence, the cells
were cultured for an additional 24 h. The conditioned
medium was collected and centrifuged at 2000 g for
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natant was filtered through a 0.22-μm pore filter (EMD
Millipore, Billerica, MA, USA) and concentrated accord-
ing to a 30 KDa molecular weight cutoff (MWCO)
(EMD Millipore) by centrifugation at 4000 g for 60 min.
A 1/5 volume of ExoQuick-TC Exosome Precipitation
Solution (System Biosciences, Inc., Palo Alto, CA, USA)
was added to the supernatant and it was incubated
overnight. The mixture was centrifuged at 1500 g for
30 min, which aspirated the supernatant, and spun
down at 1500 g for 5 min to remove residual
ExoQuick-TC. The exosome-enriched fraction was diluted
with 100 μl PBS and stored at -80 °C. The protein content
of the concentrated exosomes was determined using a
BCA protein assay kit (Pierce, Waltham, MA, USA).
MenSC-Ex were identified using transmission electron mi-
croscopy. The MenSC-Ex were confirmed to express the
exosome marker tetraspan molecules [CD63 (Abcam,
Cambridge, UK) and tsg101 (Abcam)] using Western blot
analysis.Cellular uptake and in vivo tracking of MenSC-Ex
MenSC-Ex were labeled with a 1:10 ratio of Exo-Green
(System Biosciences, Inc.). The exosomes solution was
incubated at 37 °C for 10 min. A 100 μl volume of
ExoQuick-TC was added to stop the labeling reaction.
The labeled MenSC-Ex were placed on ice (or at 4 °C)
for 30 min and centrifuged for 3 min at 14,000 rpm to
remove the supernatant, which contained excess label.
The pellet containing the labeled MenSC-Ex was resus-
pended in 500 μl of PBS, and at least 100 μl of the solu-
tion of labeled MenSC-Ex was added to approximately
1 × 105 AML12 cells in one well of a 6-well culture plate,
which was incubated for 24 h. AML12 cells were incu-
bated with 100 μl of PBS instead of MenSC-Ex as the
control. The cellular uptake of MenSC-Ex was observed
under a confocal laser microscope (Carl Zeiss, Oberkochen,
Germany).
XenoLight DiR (Perkin Elmer, Waltham, MA, USA)
was used to track exosomes in vivo. The solution of
XenoLight DiR was diluted to 300 μM in PBS. We added
the diluted XenoLight DiR solution to 10 μg of MenSC-
Ex in 1 ml PBS to obtain a final concentration of 2 μM.
The cells were incubated with MenSC-Ex at room
temperature for 30 min. A 1/5 volume of ExoQuick-TC
Exosome Precipitation Solution (System Biosciences,
Inc.) was then added to the supernatant for 30 min. The
solution was then centrifuged for 3 min at 14,000 rpm.
The pellet, which contained the fluorescently labeled
MenSC-Ex, was resuspended in 100 μl of PBS. We then
systemically administered 50 μg of MenSC-Ex via the tail
vein. IVIS analysis (Caliper Life Sciences, Hopkinton, MA,
USA) and dissections were performed after 3 h and 6 h.Antibody arrays
Human Cytokine G1000 arrays (AAH-CYT-G1000;
RayBiotech, Norcross, GA, USA) were used according
to the manufacturer’s instructions to measure the ex-
pression levels of 120 cytokines in the MenSCs and
MenSC-Ex. Positive signals were captured on glass
chips using a laser scanner (GenePix 4000B Microarray
Scanner; Molecular Devices, Sunnyvale, CA, USA), and
the observed fluorescence intensities were normalized
to the intensities of the internal positive controls. These
cytokines were screened using the following integrated
conditions: the MenSC group compared to the MenSC-Ex
group (p < 0.05) for samples with fluorescence intensity
values that exceeded 300 (RayBiotech). Differentially
expressed proteins were arranged using hierarchical clus-
tering and represented as a heat map. The heat map was
generated using R software (http://www.r-project.org/).
Cell proliferation and apoptosis analysis
A Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto,
Japan) was used to evaluate proliferation in MenSC-Ex-
treated D-GalN/LPS-induced AML12 cells. After the
cells were cultured for 24 h with 44 μg/ml D-GalN and
100 ng/ml LPS, the CCK-8 reagent was added to the
chamber, and the cells were incubated for an additional
3 h according to the manufacturer’s protocol. The optical
densities of the solutions were read at 450 nm (OD450)
and measured using a multifunctional microplate reader
(SpectraMax M5, Molecular Devices).
To analyze cell apoptosis, MenSC-Ex-treated AML12
cells that were cultured for 24 h with 44 μg/ml D-GalN
and 100 ng/ml LPS were collected, centrifuged, and then
stained with propidium iodide and Annexin V in the
dark for 30 min at room temperature using a cell apop-
tosis Analysis Kit (Sigma-Aldrich). Cell apoptosis was
then analyzed using flow cytometry.
The animal model and MenSC-Ex transplantations
To induce FHF in mice, C57BL/6 mice (20 ± 2 g) were
intraperitoneally injected with D-GalN (800 mg/kg)
(Sigma-Aldrich) and LPS (50 μg/kg) (Sigma-Aldrich).
Mice injected with an equal volume of PBS alone were
used as the model group for the FHF model (n = 10 per
model group). To evaluate the therapeutic efficacy of
MenSC-Ex on FHF, 1 μg/μl of MenSC-Ex in PBS or PBS
alone was injected into the tail veins of mice 1 day be-
fore treatment. The animals were anesthetized using
sodium pentobarbital (50 mg/kg; Solarbio Bioscience &
Technology, Shanghai, China) 6 hours after treatment
with D-GalN/LPS. The serum samples were centrifuged
at 3000 rpm for 10 min to collect clear serum to detect
the levels of alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST). A portion of liver tissue
was stored in 4% paraformaldehyde for histological and
Table 1 Primers used for qRT-PCR analysis











Chen et al. Stem Cell Research & Therapy  (2017) 8:9 Page 4 of 15immunohistochemical analysis. The remainder of the
tissue samples was washed in cold saline and preserved
at -80 °C for further analysis using reverse transcription-
polymerase chain reaction (RT-PCR). The survival rates of
the mice were determined for the 12 h period following
D-GalN/LPS challenge.
Liver function tests and ELISA
Liver function was assessed by analyzing serum alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) levels. ALT and AST levels were measured using
commercial kits (Nanjing Jiancheng Bioengineering In-
stitute, Jiangsu, China) according to the manufacturer’s
instructions.
The levels of interleukin-6 (IL-6), interleukin-1β (IL-1β),
and tumor necrosis alpha (TNF-α) were measured in serum
samples using commercially available enzyme-linked
immunosorbent assays (ELISAs) (RayBiotech) according
to the manufacturer’s instructions.
Histological, immunohistochemistry and TUNEL staining
Liver tissues were harvested from mice 6 h after treatment
with D-GalN/LPS or MenSC-Ex. Tissues were fixed in
10% buffered formalin, embedded in paraffin, sectioned to
a 5-mm thickness, and stained with hematoxylin and eosin
(H&E). The sections were imaged using an Olympus IX83
inverted microscope (Olympus, Tokyo, Japan) equipped
with Olympus cellSens software (cellSens Standard 1.9).
To perform the immunohistochemistry test, peroxid-
ase activity was blocked by incubating the sections in 3%
H2O2 for 10 min. The sections were then pretreated via
heat-mediated antigen retrieval with sodium citrate buf-
fer (pH6.0). The tissue sections were blocked in 10%
FBS for 20 min at room temperature and then incubated
with rabbit polyclonal antibodies against mouse caspase-
3 (Cell Signaling Technology, Danvers, MA, USA) over-
night at 4 °C. The slides were washed three times with
PBS for 5 min and subsequently incubated with second-
ary antibodies (Abcam). A solution of diaminobenzidine
tetrahydrochloride (DAB kit; Maixin Biotech, Fujian,
China) was used as the reaction substrate.
Apoptosis was detected in liver cells in paraffin-
embedded sections using a fluorescence terminal deox-
ynucleotidyl transferase dUTP nick-end labeling (TUNEL)
apoptosis assay kit (Vazyme, Nanjing, China) according to
the manufacturer’s instructions. Stained sections were ob-
served and photographed using an Olympus IX83 inverted
microscope equipped with Olympus cellSens software. The
number of positive cells was counted in six randomly
selected fields per slide.
DNA fragmentation analysis
Genomic DNA was extracted from liver samples accord-
ing to the instructions supplied by the manufacturer ofthe DNA Ladder kit (Beyotime, Jiangsu, China). The
DNA was then electrophoresed in a 1.5% agarose gel,
which was stained with 0.1 g/ml ethidium bromide at
140 V for 20 min.
Isolation of liver mononuclear cells
Liver mononuclear cells (MNCs) were isolated and pre-
pared as previously described [27]. Briefly, the livers of
C57BL/6 mice were passed through a 70-μm stainless
steel mesh. The precipitated cells were resuspended in
40% Percoll (Sigma-Aldrich), gently lain over 70%
Percoll and centrifuged at 2000 g for 20 min at room
temperature. The MNCs were contained in and iso-
lated from the interphase. Liver MNCs were stained
using anti-mouse CD11b, CD3, NK1.1, and F4/80
antibodies (Biolegend, San Diego, CA, USA) and sub-
jected to FACS analysis.
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR (qRT-PCR) was used to
analyze mRNA expression levels using a CFX96 Real-time
PCR Detection System (Bio-Rad, Hercules, CA, USA).
These experiments were performed according to a previ-
ously described protocol [28]. Briefly, the reaction consisted
of 1 μL of cDNA, 8.2 μL of RNAse-free water, 10 μL of
SYBR® Fast qPCR Master Mix (Takara Bio Inc., Mountain
View, CA, USA), and 0.4 μL of each gene-specific primer
(10 mM). The primer sequences are shown in Table 1. The
relative quantities of each PCR product were determined
using the following equation: RQ= 2-ΔΔCT. GAPDH served
as an internal control.
Western blot analysis
After MenSCs were collected, the cells and MenSC-Ex
were homogenized using cell lysis buffer (Cell Signaling
Technology) containing 100× phenylmethylsulfonyl fluoride
(PMSF) (Beyotime Biotechnology Inc., Shanghai, China).
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MenSCs and MenSC-Ex and placed in separate lanes to be
separated using electrophoresis on NuPAGE® Novex 10%
Bis-Tris gels (Life Technologies, Carlsbad, CA, USA). The
separated proteins were then transferred onto PVDF mem-
branes (EMD Millipore). The membranes were blocked in
0.5% bovine serum albumin (BSA) for 1 h at room
temperature and then incubated with primary antibodies at
4 °C overnight. They were subsequently incubated with
HRP-conjugated secondary antibodies (goat anti-mouse or
goat anti-rabbit, Bio-Rad) for 1 h at room temperature. Im-
munoreactive bands were visualized using enhanced en-
hanced chemiluminescence (ECL) reagent (Bio-Rad) with a
Tanon-4500 digital image system (Tanon Science & Tech-
nology, Shanghai, China).Fig. 1 Identification of MenSCs. A Representative images of MenSCs shown
cytometry analysis of the surface markers expressed on MenSCs. C Growth
15 days of culture at 50, 150, and 250 cells per square centimeterStatistical analysis
All statistical analyses were performed using GraphPad
Prism v5.0 (GraphPad Software Inc., San Diego, CA, USA).
All data represent the means ± standard deviation. One-
way analysis of variance (ANOVA) was used to determine
differences between groups. P values < 0.05 (*) or < 0.01 (**)
were considered to indicate statistical significance.
Results
Identification of MenSCs
MenSCs have morphologies and immunophenotypes that
are similar to MSCs. The MenSCs exhibited a spindle-
shaped, fibroblast-like morphology (Fig. 1A); and they
expressed high levels of CD29, CD73, CD90, and CD105
and did not express CD34, CD45, CD117, or HLA-DRat (a) scale bar = 100 μm and (b) scale bar = 100 μm. B Flow
curve of MenSCs by CCK-8 assay. D Colony count of MenSCs after
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(Fig. 1C) and displayed enhanced colony-forming (CFU-F)
ability depending on the number of cells (Fig. 1D).
Identification of MenSC-Ex
MenSC-Ex was prepared as previously described. Trans-
mission electron microscopy (TEM) showed that MenSC-
Ex displayed a round, ball-like shape and had diameters of
approximately 30–100 nm (Fig. 2A). Western blot analysis
showed that the collected MenSC-Ex expressed specific
exosomal surface markers, such as CD63 and tsg101,
which are not expressed on MenSCs (Fig. 2B). These re-
sults demonstrate that MenSC-Ex display specific charac-
teristics that are identical to those described in previous
studies of exosomes [29, 30].
Differential cytokine expression in MenSCs and MenSC-Ex
To identify molecules expressed on MenSCs and MenSC-
Ex, an antibody array was used to examine cytokine levels
(Fig. 3A). Several cytokines, including intercellular cell
adhesion molecule-1 (ICAM-1), angiopoietin-2, Axl,
angiogenin, insulin-like growth factor-binding protein 6
(IGFBP-6), osteoprotegerin, IL-6 and IL-8, were expressed
at higher levels on MenSC-Ex than on MenSCs. Among
the 120 cytokines that were evaluated in this array,
some were not expressed at detectable levels or were
expressed at extremely low levels (data not shown). The
cytokines that were differentially expressed are displayed
in a heat map (Fig. 3B). The average fluorescence inten-
sities associated with each marker are shown in Fig. 3C.
MenSC-Ex were taken up by AML12 cells in vitro and
tracked in mice in vivo
To determine whether MenSC-Ex can be taken up by
AML12 cells, we labeled MenSC-Ex with Exo-Green, a
fluorescent cell linker compound that is incorporatedFig. 2 Identification of MenSC-Ex. A Transmission electron micrograph (TEM
in MenSC-Ex using Western blot analysisinto cellular proteins. When we incubated the Exo-
Green labeled exosomes with AML12 cells, subsequently
green fluorescence in the cytoplasm of almost every
AML12 cell was observed (Fig. 4A). These results indi-
cated that a significant number of exosomes were taken
up by the AML12 cells in vitro.
To determine whether MenSC-Ex can be tracked in
C57/BL6 mice, MenSC-Ex were labeled with XenoLight
DiR. We administered the DiR-labeled MenSC-Ex into the
tail veins of C57/BL6 mice, and then evaluated their distri-
bution using in vivo imaging. At 3 h and 6 h after the in-
jection, fluorescence was detected in the liver, the lungs,
and the spleen (Fig. 4B). The in vivo fluorescence inten-
sity indicated that the signal was retained in the liver,
the lungs, and the spleen at a steady level after 3 h and
6 h. We also intravenously injected PBS as a control.MenSC-Ex inhibited apoptosis in D-GalN/LPS-induced
AML12 cells
To measure the effect of D-GalN/LPS on the viability of
AML12 cells, the ratio of its inhibitory effect was deter-
mined using a CCK-8 assay. Three different doses (5 μg,
10 μg, and 20 μg) of MenSC-Ex were found to inhibit
the effects induced by D-GalN/LPS on AML12 cells.
The data for five of the groups showed significant differ-
ences. Furthermore, the inhibitory ratio increased in a
dose-dependent manner as the dose of MenSC-Ex in-
creased. These results demonstrated that MenSC-Ex exert
an anti-apoptosis effect on AML12 cells (Fig. 5A).
To determine the effects of MenSC-Ex on D-GalN/
LPS-induced AML12 apoptosis, AML12 cells were pre-
treated with either exosomes or PBS (both in FBS-free
medium) for 24 h. The cells were then co-incubated
with D-GalN/LPS for an additional 6 h. Apoptosis was
measured in the AML12 cells using Annexin V/PI
(Fig. 5B). When cells were treated with D-GalN/LPS, the) of MenSC-Ex, scale bar = 200 nm. B CD63 and tsg101 were detected
Fig. 3 Cytokine expression in MenSC-Ex and MenSCs. A Representative array images are shown (n = 4). B Cytokines that were differentially
expressed are shown as a heat map. C The fluorescence intensities of the indicated cytokines
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was higher than in the MenSC-Ex-treated group. There
were significant differences in the proportions of apop-
totic cells between the three different doses of MenSC-
Ex (Fig. 5C). These results suggest that MenSC-Ex in-
hibit D-GalN/LPS-induced apoptosis in AML12 cells.MenSC-Ex enhanced the survival rate and improved liver
function in a D-GalN/LPS-induced mouse model of FHF
Mice began to die at 6 h after they were injected with
D-GalN/LPS, and the mortality rate in these mice
reached 80% within 12 h. However, mice pretreated with
MenSC-Ex had significantly reduced mortality (Fig. 6A).
Fig. 4 Uptake and tracking of MenSC-Ex in AML12 cells and mice. A Intracellular Exo-Green-labeled exosomes were detected in AML12 cells using
confocal fluorescence microscopy. Scale bar = 50 μm (B). Analysis of XenoLight DiR-labeled exosomes after systemic administration was detected
using an in vivo imaging system (IVIS)
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ited a lower protective effect than was observed in the
mice treated with MenSC-Ex.
D-GalN/LPS increased the levels of ALT and AST in
the serum of C57/BL6 mice, resulting in a significant in-
crease in liver injury over the level observed in the PBS
group, the silymarin-treated group, and the MenSC-Ex-
treated group. Mice pretreated with MenSC-Ex showed
significantly lower levels of ALT and AST than were
observed in the group treated with D-GalN/LPS alone
(p < 0.01). There was no significant difference between the
MenSC-Ex group and the silymarin group (Fig. 6B, C).
In the FHF mouse model, real-time PCR data con-
firmed that MenSC-Ex significantly downregulated
hepatic levels of TNF-α, IL-6, and IL-1β, suggesting
that MenSC-Ex prevented D-GalN/LPS-induced FHF
by inhibiting the production of inflammatory cytokines
(p < 0.01) (Fig. 6D-F). Furthermore, the results of
ELISA showed that D-GalN/LPS increased the levels ofthe inflammatory cytokines TNF-α, IL-6, and IL-1β in
C57/BL6 mouse serum. However, treatment with
MenSC-Ex resulted in significantly lower levels of
TNF-α, IL-6, and IL-1β than were observed in the D-
GalN/LPS-induced mice (p < 0.01) (Fig. 6F-I).
To assess general morphological changes in the liver,
liver tissue sections were mounted and stained with
H&E (Fig. 6J). The normal groups showed a normal liver
architecture. The groups administered with D-GalN/LPS
displayed severe centrilobular focal necrosis, apoptosis
and inflammation. Mice pretreated with MenSC-Ex and
then induced with D-GalN/LPS showed a much lower
degree of hepatocellular necrosis and inflammation than
were observed in the D-GalN/LPS group.
MenSC-Ex inhibited apoptosis in hepatocytes and the
expression of caspase-3 in D-GalN/LPS-induced FHF
Apoptosis was detected in hepatocytes using fluorescent
TUNEL staining. A large number of TUNEL-positive
Fig. 5 MenSC-Ex treatment inhibited apoptosis in D-GalN/LPS-induced AML12 cells. a The percentage of MenSC-Ex that was produced in
proliferating D-GalN/LPS-induced AML12 cells. b Annexin V/PI staining of D-GalN/LPS-induced AML12 cells. c The percentage of cells
undergoing apoptosis was measured. Each experiment was repeated three times; *p < 0.05
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from mice treated with D-GalN/LPS. However, few
TUNEL-positive hepatocytes were observed in the
livers of mice in the MenSC-Ex and silymarin groups.
There were substantial differences in the number of apop-
totic hepatocytes between the D-GalN/LPS and MenSC-Ex
groups (Fig. 7A).
Genomic DNA fragmentation was assayed to confirm
that hepatocytes were undergoing apoptosis. DNA frag-
mentation was observed in the livers of mice treated
with D-GalN/LPS, while no DNA fragmentation was ob-
served in the livers of the MenSC-Ex group, and only a
small amount of DNA fragmentation was observed in
the silymarin group (Fig. 7B).
Apoptosis is a physiological process that is involved in
D-GalN/LPS-induced FHF. At 6 h after MenSC-Ex
transplantation, immunohistochemistry and PCR for
caspase-3 showed that there were caspase-3-positive
cells in the MenSC-Ex livers (p < 0.01), the PBS and
silymarin livers exhibited lower levels than the D-
GalN/LPS group (Fig. 7C, D).MenSC-Ex inhibited macrophage proliferation in liver
mononuclear leukocytes in D-GalN/LPS-induced FHF
The percentage of natural killer (NK) cells that were in
the liver was calculated by multiplying the percentage of
CD3−NK1.1+ (NK) cells by the total number of lympho-
cytes per liver. NK cells (CD3−NK1.1+) and total T cells
(CD3+NK1.1−) were also detected in the liver using flow
cytometry. The results showed that treatment with D-
GalN/LPS induced NK cells to accumulate in the liver
(p < 0.01) (Fig. 8A, C). Administration of MenSC-Ex sig-
nificantly prevented liver injury. There was no significant
difference between the percentage of NK cells in the
MenSC-Ex and silymarin groups. Furthermore, the severe
liver injury that was triggered in the C57/BL6 mice that
were treated with D-GalN/LPS indicated that NK cells
could potentially mediate D-GalN/LPS-induced FHF.
Flow cytometry analysis was used to detect mono-
nuclear leukocytes in the livers of D-GalN/LPS-induced
FHF mice. CD11b is a marker of mononuclear leuko-
cytes, and F4/80 is a specific marker of macrophages, in-
cluding Kupffer cells. In normal mice, the percentage of
Fig. 6 MenSC-Ex transplantation enhanced survival rates and improved liver function in a D-GalN/LPS-induced FHF mouse model. a Survival
curves after mice were injected with D-GalN/LPS (n = 10). b and c Serum levels of ALT and AST were measured at 6 h after stimulation with
D-GalN/LPS. d-f Liver levels of the IL-6, IL-1β, and TNF-α mRNAs were also detected using real-time RT-PCR at 6 h after the nice were injected with
D-GalN/LPS. g-i Serum levels of IL-6, IL-1β, and TNF-α were determined using ELISA. j Liver sections were obtained from D-GalN/LPS-induced mice
and analyzed using H&E staining (n = 10 per group, **p < 0.01). Scale bar = 50 μm
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stimulated with D-GalN/LPS, this percentage significantly
increased to 26.7%. However, it decreased to 11.7% after
the mice were treated with MenSC-Ex (p < 0.01) (Fig. 8B,
D). There was no significant difference in the percentage
of CD11b + cells between the MenSC-Ex and silymarin
groups. These results demonstrated that MenSC-Ex in-
hibits the recruitment of inflammatory cells and reduces
the number of inflammatory cells in liver. However,
there were no significant differences in the numbers of
CD11b+/F4/80+ cells among all four groups.Discussion
Because they are easy to collect, isolate, and there are no
ethical considerations associated with their use, MenSCs
have become a useful tool for exploring how MSCs can
be used to treat tissue injuries. Our group previously re-
ported that MenSCs are a promising therapeutic method
for treating some diseases, such as liver injury and type
1 diabetes [12, 31]. Based on these benefits, we chose to
use MenSCs as a source of stem-cell-derived exosomes.
In this study, MenSC-Ex were used in mice, and no evi-
dence of immune rejection was observed when MenSC-
Fig. 7 MenSC-Ex inhibited hepatocyte apoptosis and caspase-3 expression in D-GalN/LPS-induced FHF. A TUNEL assay showing liver sections at
6 h after D-GalN/LPS-induced FHF. Apoptotic cells were stained with green fluorescence, and nuclei were stained red, indicating PI. Scale
bar = 50 μm (B). Analysis of genomic DNA fragmentation in liver tissues obtained at 6 h after D-GalN/LPS injection in the (a) normal group,
(b) model group, (c) silymarin group, and (d) MenSC-Ex group. C Immunohistochemical analysis of caspase-3 expression in apoptotic liver
cells at 6 h after D-GalN/LPS injection. Scale bar = 50 μm (D) The expression of caspase-3 was evaluated in apoptotic liver cells at 6 h after
D-GalN/LPS injection (**p < 0.01)
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exosomes from MenSCs. The MenSC-Ex had diameters
of approximately 30–100 nm and expressed the CD63
and tsg101 proteins.
Several articles have shown that MSCs may perform
paracrine functions that might play therapeutic roles in
disease states [32–35]. It has been reported that human
bone marrow MSC-derived microvesicles contain RNAs
and surface proteins that had therapeutic effects in a
mouse model of acute tubular injury, in which they en-
hanced survival [36–38]. In the present study, we used
an antibody array to show that MenSC-Ex contain many
cytokines, including ICAM-1, angiopoietin-2, Axl, angio-
genin, IGFBP-6, osteoprotegerin, IL-6, and IL-8. Gener-
ally, IL-6 has been known to act as a pro-survival factor,
which can stimulate hepatocyte proliferation [39, 40].
Osteoprotegerin could regulate bone resorption, model-
ing, and remodeling, which is mainly secreted by osteo-
blasts [41, 42]. Meanwhile, IGFBP-6 could control the
differentiation of cells and prevent the apoptosis and aging
of human fibroblasts [43, 44]. IL-8, a chemokine of the
immune system, could recruit neutrophils, endothelialcells, and macrophages to sites of injured tissues [45, 46].
Recently, Ren et al. found that MSCs express a low level
of ICAM-1, which play a critical role in MSC-mediated
immunosuppression [47]. Axl is a transmembrane recep-
tor tyrosine kinase, expressed widely in the body, which
could regulate apoptosis, migration and proliferation of
cells through a variety of signaling pathways [48]. Accord-
ing to Cai et al., angiopoietin-2 could promote the gener-
ation of new vessels in retina under hypoxia [49].
Angiogenin is capable of stimulating cell proliferation and
promoting cell survival, which is predominately produced
by the liver and normally circulating in human body fluid
[50]. Therefore, all of the cytokines that we found were
expressed in MenSC-Ex may have potentially therapeutic
effects on diseases.
We evaluated liver cells in vivo and in vitro using
fluorescence-labeled MenSC-Ex. Experiments in which
treated cells or mice with MenSC-Ex provided initial in-
sights into potential cellular therapies that might involve
these structures. We observed clear fluorescence in AML12
cells and mice post-treatment with fluorescence-labeled
MenSC-Ex. These data suggest that MenSC-derived
Fig. 8 MenSC-Ex inhibited proliferation in macrophages in cultures of liver mononuclear leukocytes in D-GalN/LPS-induced FHF. a Mononuclear
leukocytes obtained from the liver were co-stained with anti-mouse CD3 and NK1.1 antibodies at 6 h after D-GalN/LPS-induced FHF. b Mononuclear
leukocytes in the liver were co-stained with anti-mouse CD11b and F4/80 antibodies. c The percentages of NK cells (CD3−NK1.1+) in the total
population of mononuclear leukocytes are shown (**p < 0.01). d The percentages of CD11b+ cells out of the total population of mononuclear
leukocytes are shown (**p< 0.01)
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functions within injured livers.
We used a D-GalN/LPS-induced mouse model of FHF
to explore the mechanisms underlying clinical liver fail-
ure. In the present study, administering an injection
containing MenSC-Ex prior to D-GalN/LPS reduced the
circulating levels of TNF-α, IL-6, and IL-1β, decreased
hepatic apoptosis, improved liver function, and eventu-
ally lowered the fatality rate in FHF mice. Our findings
also demonstrated that MenSC-Ex inhibited hepatocyte
apoptosis and enhanced survival in mice treated with D-
GalN/LPS. Specifically, an intravenous injection of
MenSC-Ex reversed organ failure. All of our results
showed that MenSC-Ex functioned to affect important
pharmacological characteristics.
According to the results of our experiments, the
mechanisms that explain the therapeutic effect of
MenSC-Ex on D-GalN/LPS-induced FHF involves theinhibitory immunomodulation of activated MNC pro-
liferation or the activation of apoptosis-associated pro-
teins. In the present study, one dataset suggested that
there were more MNC in the D-GalN/LPS group than
in the group treated with MenSC-Ex and the positive
control group. One possible explanation for this result
is that, in vivo MenSC-Ex may inhibit MNC proliferation,
and MenSC-Ex may thereby act as crucial contributors to
the observed reductions in FHF. The amount of cleaved
caspase-3 expressed in the D-GalN/LPS group was lower
than the amount expressed in the MenSC-Ex, but there
was no difference with the positive control group. These
data suggest that the activation of the apoptosis-related
protein cleaved caspase-3 is another process that contrib-
utes to the mechanisms by which MenSC-Ex inhibit liver
apoptosis in D-GalN/LPS-induced FHF.
NK cells are innate immune cells. A variety of artifi-
cially synthesized and natural products have been tested
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[51]. Microbial (especially viral) invasion, tumor metas-
tasis, and environmental materials are also capable of
recruiting and activating NK cells in particular tissues or
organs [52, 53]. Approximately 30–40% and 10–20% of
the total number of MNC cells are NK cells in the livers
of humans and mice, respectively [54, 55]. Some recent
reports have shown that NK cells are involved in the
pathogenesis of human hepatitis and animal models of
liver injury [56–59]. D-GalN/LPS-induced FHF is a
macrophage-mediated model of septic hepatitis [60, 61].
In recent years, a considerable amount of data has accu-
mulated regarding the involvement of NK cells in the
pathogenesis of sepsis, a systemic inflammatory process
that is induced by bacterial lipopolysaccharide (LPS) [62].
According to data obtained by our group, D-GalN/LPS
acts directly on NK cells to accelerate the increase in the
number of NK cells in the injured liver. When cells or ani-
mals were treated with MenSC-Ex, the number of NK
cells decreased. The reason that MenSC-Ex inhibited the
increase in NK cells that was observed in the D-GalN/
LPS-only treated livers remains unknown.
Caspase-3 is the most important apoptosis-associated
protein [63]. The activation of caspase-3 induces an en-
zymatic cascade in mammalian cells that is viewed as an
‘executioner’ of apoptosis [64]. In addition, the first step
in hepatocellular apoptosis requires the activation of
caspase-3 [65]. In the present study, mice treated with
MenSC-Ex exhibited lower levels of caspase-3 protein in
the liver than were observed in the D-GalN/LPS-treated
group. This finding suggests that the caspase-3-mediated
death receptor pathway is one of the main mechanisms
by which D-GalN/LPS induce hepatocyte apoptosis.
Studies aimed at exploring the role of apoptosis proteins
in D-GalN/LPS-induced liver apoptosis may provide in-
sights into potential mechanisms through which MenSC-
Ex can be used to treat D-GalN/LPS-induced FHF.
Silymarin has the therapeutic effect of restoring the
normal liver functions [66]. In our study, silymarin had
the ability of improving liver function in FHF mice, and
its regenerative capabilities were the same as MenSC-Ex.
Although we demonstrated that MenSC-Ex amelio-
rated D-GalN/LPS-induced FHF in mice and explored
mechanisms that may potentially underlie this effect in
the present study, there are still many challenges to
overcome before applications involving MenSC-Ex can
be used in clinical medical practice. For example, FHF
occurs rapidly, and when patients present at the hospital,
they are almost always in the terminal stage of the dis-
ease. FHF causes the massive death of liver cells, and
humans are much larger than mice and most other
model mammals. Therefore, when MenSC-Ex are used
to treat this disease, appropriate attention must be paid
to the dose. In this study, MenSC-Ex reduced apoptosisin hepatocellular cells and enhanced longevity in FHF
mice. However, treatments that do not renew hepato-
cellular tissues may be insufficient for treating FHF.
Therefore, identifying methods to use MenSC-Ex in
therapeutics remains a necessity for developing these
cells into clinically applicable strategies.
Conclusions
In this study, we present preliminary evidence demon-
strating the potential of MenSC-Ex for reducing ful-
minant hepatic failure (FHF). These data suggest that
MenSC-Ex transplantation deserves further study as an
adjunctive or alternative approach for treating FHF.
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